Advertisement

Treatment of hyperammonemia with carbamylglutamate in rats

Authors

  • Eugenio Grau,

    1. Instituto de Investigaciones Citológicas, Centro Asociado del CSIC, Amadeo de Saboya, 4, 46010 Valencia, Spain
    Search for more papers by this author
  • Vicente Felipo,

    Corresponding author
    1. Instituto de Investigaciones Citológicas, Centro Asociado del CSIC, Amadeo de Saboya, 4, 46010 Valencia, Spain
    • Instituto de Investigaciones Citológicas, Amadeo de Saboya, 4, 46010 Valencia, Spain
    Search for more papers by this author
  • María-Dolores Miñana,

    1. Instituto de Investigaciones Citológicas, Centro Asociado del CSIC, Amadeo de Saboya, 4, 46010 Valencia, Spain
    Search for more papers by this author
  • Santiago Grisolía

    1. Instituto de Investigaciones Citológicas, Centro Asociado del CSIC, Amadeo de Saboya, 4, 46010 Valencia, Spain
    Search for more papers by this author

Abstract

A protein-free diet causes a paradoxical increase of blood ammonia levels that seems to be due to decreased liver content of acetylglutamate, the physiological activator of carbamylphosphate synthetase. The purpose of this study was to assess whether oral administration to rats of carbamylglutamate, a metabolically stable activator of carbamylphosphate synthetase, could decrease the blood ammonia levels increased by the protein-free diet. We show that ingestion of moderate doses of carbamylglutamate increased about sixfold the liver content of carbamylphosphate synthetase activators and restores to normal values the blood ammonia levels. Excess ammonia is eliminated in urine as urea. These results indicate that carbamylglutamate, which is not toxic, could be useful in the treatment of hyperammonemia, especially in cirrhosis. (Hepatology 1991;15:446–448).

Ancillary